Acute kidney injury in COVID-19 in United Kingdom [COVID-19] [UPH]
Research type
Research Study
Full title
Acute Kidney Injury In COVID-19 Disease in United Kingdom
IRAS ID
284091
Contact name
Nitin Kolhe
Contact email
Sponsor organisation
University Hospitals of Derby and Burton NHS Trust
Clinicaltrials.gov Identifier
UHDB/2020/050 , Local reference number
Duration of Study in the UK
0 years, 11 months, 25 days
Research summary
Research Summary
On 31st December 2019, a cluster of pneumonia cases were detected in Hubei province of China where the cause was unclear. The cause for these cases was subsequently identified as a virus which was referred to as SARS-CoV-2, and the associated disease as COVID-19. This evolved rapidly into a global pandemic with first case reported in UK as early as on 30th January 2020. As of 30th April 2020, there have been 3.05 million laboratory confirmed cases world-wide with 161,145 cases in United Kingdom in 539,768 cases tested for COVID-19. The epidemiology of COVID-19 has differed in China, US and Italy which have different demographic characteristics, testing methods and different ways to curb the spread of infection which can be altered by many things, including behaviour, and the stringent social distancing measure.Though the pandemic started in China, as of 30th April 2020, it has reported only 58.32 cases per million people (pmp) as compared to United kingdom which has reported 2433.8 cases pmp. This has resulted in different epidemiology of COVID-19 and organ system involvement. Lung involvement in the form of alveolar haemorrhages and respiratory failure has been well document in patients with COVID and has been focus of attention, however, other organs are also affected in COVID-19, but there has been limited information kidney involvement in COVID patients. [Study relying on COPI notice]
Summary of Results
Recent reports have suggested that some patients with Coronavirus Disease 2019 (COVID-19) develop acute kidney injury (AKI). There is a need to better understand risk factors for AKI in patients with COVID-19. It is also unclear if AKI in patients with COVID-19 differs from AKI due to other causes.
In this study, we examined risk factors for AKI in patients with COVID-19 and also compared AKI in COVID-19 with AKI due to other causes. We found that males and patients of nonwhite ethnicity as well as those with comorbidities were at increased risk of developing AKI in COVID-19. AKI was associated with a 3-fold increase in mortality in COVID-19 patients. Patients with COVID-19 and AKI had higher mortality (60.5% versus 27.6%) than patients with AKI due to other causes, and COVID-19 was an independent predictor of mortality associated with an almost 4-fold odds of death.
COVID-19 frequently causes AKI, and when it does, it is associated with a higher mortality than COVID-19 without AKI or AKI due to other causes. Patients with COVID-19 should be monitored for early evidence of AKI so that preventive measures can be taken to avoid AKI.REC name
Wales REC 2
REC reference
20/WA/0153
Date of REC Opinion
14 May 2020
REC opinion
Favourable Opinion